Oscar Health Inc. Surges 6.69% After ACA Subsidy Extension Passes

Written by Emily J. Thompson, Senior Investment Analyst

OSCR-0.39%

Source: Yahoo Finance

Updated: 2d ago

0mins

Source: Yahoo Finance

Stock Surge: Oscar Health Inc. rose 6.69% in after-hours trading to $18.04 per share, reflecting optimistic market sentiment regarding the company's future, particularly in light of the ACA subsidy extension.
Policy Impact: The U.S. House of Representatives passed a bill extending Affordable Care Act subsidies for three more years, which is expected to lower health insurance costs for millions of Americans, significantly improving Oscar Health's business outlook due to its heavy reliance on the ACA exchange market.
Analyst Upgrade: Barclays upgraded Oscar's stock rating from 'Underweight' to 'Equal-Weight' and raised its price target from $13 to $18, further fueling the stock's rise and indicating strong market confidence in its future performance.
Year-to-Date Performance: Oscar's stock has increased 16.71% year-to-date, showcasing strong performance in the overall market, with positive price trends in both short and long terms despite poor momentum rankings.

OSCR

$17.66+Infinity%1D

Analyst Views on OSCR

Wall Street analysts forecast OSCR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSCR is 16.06 USD with a low forecast of 11.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Analyst Rating

1 Buy

1 Hold

3 Sell

Moderate Sell

Current: 17.730

Low

11.00

Averages

16.06

High

25.00

Current: 17.730

Low

11.00

Averages

16.06

High

25.00

UBS

Sell -> Neutral

upgrade

$12 -> $17

2026-01-09

New

Reason

UBS

Price Target

$12 -> $17

2026-01-09

New

upgrade

Sell -> Neutral

Reason

UBS upgraded Oscar Health to Neutral from Sell with a price target of $17, up from $12. The firm believes that despite the expiration of the enhanced subsidies, Oscar's enrollment in the exchanges are holding up better than feared. UBS says the shares are fairly priced at this level.

Barclays

Andrew Mok

Underweight -> Equal Weight

upgrade

$13 -> $18

2026-01-05

Reason

Barclays

Andrew Mok

Price Target

$13 -> $18

2026-01-05

upgrade

Underweight -> Equal Weight

Reason

Barclays analyst Andrew Mok upgraded Oscar Health to Equal Weight from Underweight with a price target of $18, up from $13. The firm sees managed care stocks benefiting in 2026 from the prospects of margin expansion and rotation away from artificial intelligence-related stocks toward "de-rated underperformers." Oscar is priced attractively as the market is currently over-discounting the negative outcomes from expiring subsidies, the analyst tells investors in a research note.

Jefferies

downgrade

$12

2025-12-22

Reason

Jefferies

Price Target

$12

2025-12-22

downgrade

Reason

Prospects for an Enhanced Advance Premium Tax Credit extension have diminished, with early Idaho open enrollment period enrollment up 3% year over year but offset by expected non-effectuation, higher voluntary disenrollment, and increased buy-down into bronze plans, Jefferies tells investors in a research note. In Georgia, Kaiser's pause on new enrollment heightens SEP-related medical loss ratio risk for Oscar Health, which is positioned with the first- and second-lowest-cost Silver plans in the state's four most populous counties, the firm says. Jefferies has an Underperform rating and $12 price target on Oscar Health shares.

Stephens

Equal Weight

initiated

$17

2025-12-10

Reason

Stephens

Price Target

$17

2025-12-10

initiated

Equal Weight

Reason

Stephens initiated coverage of Oscar Health with an Equal Weight rating and $17 price target. The firm believes the company's "pure-play focus" to the Affordable Care Act exchanges can be viewed as a "two-way street." The policies that drove Oscar towards profitability are also driving near-term uncertainty to its long-term growth trajectory, the analyst tells investors in a research note.

About OSCR

Oscar Health, Inc. is a healthcare technology company built around a full stack technology platform. The Company's offerings include its insurance business and +Oscar Platform. Its health plans are offered in the individual market. The individual market primarily consists of policies purchased by individuals and families through health insurance marketplaces, established by the ACA and operated by the federal government, as well as other marketplaces operated by individual states. Individuals and families may also purchase policies in the individual market off-exchange. Employees whose employers have chosen to offer an Individual Coverage Health Reimbursement Arrangement (ICHRA) are also able to purchase its health plans. It offers health plans in the individual market under the five metal plan categories defined by the ACA: Catastrophic, Bronze, Silver, Gold, and Platinum. Through the +Oscar platform, the Company deploys its technology to help others throughout the healthcare system.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.